Trial results

$MAZE — MZE782

Maze Therapeutics, Inc. (MAZE) MZE782: trial results in Phenylketonuria (PKU), 2027.

Research by Catalyst Intel

The catalyst

"In August 2026, we announced that the Phase 2 proof-of-concept trial of MZE782 in patients with PKU has initiated and we anticipate reporting topline data from this trial in 2027."

— Maze Therapeutics, 10-Q filed 2026-11-09 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

MAZE-MZE782-2026

Company

Maze Therapeutics, Inc.

Kind

Trial results

Indication

Phenylketonuria (PKU)

Window

2027-01-01 – 2027-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.